(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the patient’s health. Now, doctors are rethinking that approach. The LION, Lymphadenectomy in Ovarian Neoplasms, trial … Continued
(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients. Researchers, including OCRA grantees Illana Chefetz, PhD and Ronald Buckanovich, MD, PhD, identified a new drug, 673A, that finds and destroys stem-like ovarian cancer cells. Stem-like cells are … Continued
(March 12, 2019) “The President’s proposed FY2020 budget released by the White House on Monday seeks to cut medical research funding at the National Cancer Institute (NCI) by 15 percent – almost $900 million dollars compared to FY2019 funding. The budget also slashes the Centers for Disease Control’s (CDC) Chronic Disease Program by almost 20 … Continued
(March 1, 2019) OCRA mourns the loss of our beloved board member and friend, Lori Newcomb. We are profoundly grateful for her vision and dedication in creating Newk’s Cares along with her loving husband, Chris, to support ovarian cancer research through their family business, Newk’s Eatery. Her unwavering and selfless commitment to help other women … Continued
(February 28, 2019) Toni Harris, 22, is shaking up the world of college football, and making history as the first female to earn a scholarship to play at a 4-year university. And she’s not only paving the way for future generations of women to follow their dreams in the sport – she’s also inspiring ovarian … Continued
Curious about the status of ovarian cancer research and treatments? Want to meet other survivors? You need to attend OCRA’s Ovarian Cancer National Conference. July 12-14, 2019Seattle, WAHyatt Regency Seattle Early Bird Registration is now open! OCRA’s Ovarian Cancer National Conference® is the largest, most trusted conference for ovarian cancer survivors, caregivers, supporters and experts. … Continued
(February 26, 2019) Ovarian Cancer Research Alliance is pleased to announce Beth Y. Karlan, M.D as our new chair of OCRA’s Scientific Advisory Committee. Our Scientific Advisory Committee is comprised of 24 illustrious and respected leaders in research on treating women with ovarian cancer. Dr. Karlan is Professor and Vice Chair of Women’s Health Research … Continued
(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer. Because mucinous patients don’t typically do particularly well on regimens usually used to treat the more common … Continued
Our menu is heating up! Here’s what you can enjoy at Turn Up the Heat DC on March 5th. For one night only, treat yourself to all the foodie delights that DC’s most talented female chefs, mixologists and restaurateurs have to offer, including: And so much more! Check out our ever-expanding lineup of female culinary superstars bringing … Continued
OCRA is pleased to announce we have earned our NINTH consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, organizational transparency, and accountability, as we continue to strive toward cures for ovarian cancer. A 4-star … Continued
February 4th is World Cancer Day. Today, millions of people across the globe raise a collective voice for progress. Against cancer in its many insidious forms, and for access to treatments and care for those who need it, no matter where they live. As the leading organization in the world fighting ovarian cancer from all … Continued
(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat ovarian cancer. The antihypertension drug used in a phase II clinical trial, losartan, aids the body in … Continued
Get email updates about research news, action alerts, and ways to join the fight.
